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The central theme of personalized medicine is the premise that an individual’s unique physiologic characteristics
play a significant role in both disease vulnerability and in response to specific therapies. The major goals of
personalized medicine are therefore to predict an individual’s susceptibility to developing an illness, achieve
accurate diagnosis, and optimize the most efficient and favorable response to treatment. The goal of achieving
personalized medicine in psychiatry is a laudable one, because its attainment should be associated with a marked
reduction in morbidity and mortality. In this review, we summarize an illustrative selection of studies that are laying
the foundation towards personalizing medicine in major depressive disorder, bipolar disorder, and schizophrenia. In
addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an
emphasis on novel biomarkers and neuroimaging.
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The foundation of personalized medicine centers on the
assumption that an individual’s unique characteristics
play a significant role in tailoring their therapies. Such
characteristics include: genetic alterations and epige-
netic modifications, clinical symptomatology, observ-
able biomarker changes, and environmental factors [1].
The goals of personalized medicine are to predict the
individual’s susceptibility to disease, achieve an accurate
diagnosis, and result in an efficient and favorable re-
sponse to treatment (Figure 1). Although there are
clearly some very successful examples of personalized
medicine, especially in oncology, relatively few such
examples exist in psychiatry [2]. In this review, we
summarize an illustrative selection of the advancements
toward personalizing medicine in major depressive dis-
order (MDD), bipolar disorder (BD), and schizophrenia
(SZ). We also discuss some new approaches currently
being used and how they are likely to affect the field in
the years to come.* Correspondence: cnemeroff@med.miami.edu
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Genetics
One major expectation of personalized medicine is the
ability to determine susceptibility or protective factors
imparted through genetic change. Interestingly, in the
era of genome-wide association studies (GWAS), the
majority of replicable findings do not pinpoint common
genes underlying susceptibility or protection from dis-
ease; instead, our current understanding centers pri-
marily on rare genetic variants, although a number of
common variants have furthered understanding as well.
However, both common and rare variants account for
relatively small percentages of heritability, and far greater
percentages are still attributed to ‘missing heritability’. Of
the diseases reviewed in this report, no variation confers
an autosomal dominant mendelian inheritance typical of
Huntington’s disorder [3]; moreover, no single genetic
change has shown an effect on heritability percentage that
is in double digits. Nonetheless, there have been seminal
genetic findings, each deepening our understanding of the
major psychiatric illnesses. A sample of such findings in
MDD, BD, and SZ is given below.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MDD has a strong genetic component, with an estimated
40 to 70% of the risk for developing MDD thought to be
genetic [4]. Prominent findings in susceptibility studies of
MDD include several polymorphisms in the serotonergic
system, and in various elements of the hypothalamic-
pituitary-adrenocortical (HPA) axis.
Genes involved in the serotonergic neural system have
been intensively scrutinized in candidate gene and link-
age studies in MDD for a number of reasons: this system
is a major target of several antidepressants, and patients
with MDD have alterations in multiple components
of the serotonin system [5,6]. Polymorphisms and vari-
able number tandem repeat regions (VNTR) in the 5-
hydroxytryptamine (5HT; serotonin) transporter (5-HTT)
gene have been associated with development of MDD. In
1996, Ogilvie and colleagues identified three novel alleles
of a 5-HT VNTR region, and identified an association be-
tween the nine-copy VNTR allele and risk for developing
MDD [7]. In a group of 466 German patients with MDD
and 836 controls, Hoefgen et al. [8] reported a significant
increased frequency of a 44-base pair insertion/deletion
polymorphism in the 5′ promoter region of the 5-HTT
gene (5-HT transporter-linked polymorphic region; 5-
HTTLPR) in patients with MDD relative to controls. Fur-
thermore, this 5-HTTLPR polymorphism has been studiedFigure 1 Personalized medicine. Forefront shows the schematic of the v
genetic alterations, epigenetic modifications, clinical diagnostics, biomarker
phenotypic profile, the psychiatrist is in a better position to either predict s
allows for therapy targeted to the individual. Background: each individual w
phenotypic profile.extensively both in the relationship between MDD and en-
vironmental factors and in the pharmacologic response to
treatment (as discussed in the sections on ‘Environmental
factors’ and ‘Prediction of treatment response,’ respectively).
A rate-limiting enzyme involved in serotonin synthe-
sis, tryptophan hydrolylase (TPH), has been implicated
in susceptibility for MDD by a number of reports, al-
though attempts at replication have shown discordant
findings [9]. Homologs 1 and 2 of the TPH gene (TPH1
and TPH2, respectively), have both been associated with
MDD susceptibility. Although both TPH1 and TPH2
are involved in serotonin synthesis, their distribution is
markedly different. TPH1 is found primarily in the peri-
phery, with effects on melatonin synthesis, hemostasis, and
immune system function. Conversely, TPH2 is expressed
in the CNS, with central effects on sleep, aggression, food
intake, and mood [10]. Two groups [11,12] analyzed TPH1
single-nucleotide polymorphism (SNP) and haplotype dif-
ferences between participants with depression and control
participants. In the former study, Nash et al. related quan-
titative phenotypes of depression in a community-based
sample of 119 sibling groups to genetic alterations in
TPH1, and identified a significant association between
MDD susceptibility and a microsatellite downstream of
TPH1 [11]. In the latter study, Gizatullin et al. conducted a
genetic screen of 228 patients with MDD and 253 healthyarious factors that play into developing a unique phenotypic profile:
changes, and environmental changes. Upon obtaining a unique
usceptibility to disease or make an accurate diagnosis. This, is in turn,
ill have differences in these components, giving rise to a unique
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with MDD [12].
With respect to TPH2, Zill et al. [13] identified two
SNPs (rs1386494 and rs1843809) associated with MDD in
a sample of 300 Caucasian patients with MDD and 265
healthy controls. Subsequently, Zhang et al. searched for a
novel loss-of-function mutation, G1463A, which they had
identified and characterized in the previous year in sample
of 87 patients with MDD and 219 controls [14,15]. The
authors found that this mutation was significantly more
common in patients with MDD than in controls, and
suggested that defects in brain serotonin synthesis may be
an important contributor to MDD susceptibility [15]. A
subsequent study by Garriock et al. [16] failed to replicate
these findings in a population similar in ethnicity and
gender distribution to that of Zill et al. [13] Serretti et al.
evaluated TPH2 SNPs in MDD, BD, and SZ in Korean
psychiatric inpatients and controls; their findings sug-
gested that TPH2 SNPs are not associated with MDD, BD,
or SZ [17]. In a meta-analysis of TPH2 genetic polymor-
phisms and MDD, Gao et al. examined 74 TPH2 SNPs
published through the end of October 2011, and using
fixed-effects modeling, they found that two SNPs,
rs4570625 and rs17110747, were associated with MDD
susceptibility. The relationship between SNP rs4570625
and MDD was more robust, remaining significant using
more conservative random-effects calculations [9]. Notably,
this SNP was not one of the SNPs reported in the Zill et al.
or Zhang et al. studies, although there have been later re-
ports suggestive of a minor role for rs4570625 in MDD as
well as in SZ, panic disorder, obsessive-compulsive dis-
order, and attention-deficit hyperactivity disorder [18-22].
For almost five decades, hyperactivity of the HPA axis
has been reported, and this is suggested to be contribu-
tory to depressive symptomatology [23]. Accordingly,
the components of the HPA axis provides numerous
genes that might be associated with risk for MDD, in-
cluding, but not limited to, a key component of the
glucocorticoid receptor complex, FK506-binding protein
5 (FKBP5), corticotropin-releasing hormone receptor 1
(CRHR1) and corticotropin-releasing hormone-binding
protein (CRHBP) [1]. In 2004, Binder and colleagues eval-
uated several genes that might be responsible for the HPA
hyperactivity characteristic of depression. They identified
SNPs in FKBP5 associated with increased recurrence of
MDD episodes and to a more rapid therapeutic response
to antidepressant therapy (discussed in the section ‘Pre-
diction of treatment response’) [24]. A 2009 study by
Tatro et al. genotyped two SNPs in FKBP5, rs3800373 and
rs1360780, in 60 frozen brain samples distributed over five
clinical groups: MDD, MDD with psychosis, HIV-positive
with MDD, and HIV-positive and HIV-negative controls.
The rs3800373-CC genotype was found significantly more
frequently in the MDD and MDD with psychosis groupsthan would be expected based on published allelic fre-
quencies. The authors also reported that rs1360780 allele
frequencies differed significantly from the expected allelic
frequencies in the MDD and MDD with psychosis groups
[25]. Using a sample of 155 European adolescents with
MDD from the TORDIA (Treatment of SSRI (selective
serotonin reuptake inhibitor)-Resistant Depression in
Adolescents) trial, Brent et al. provided preliminary reports
of two FKBP5 genotypes (rs1360780-TTand rs3800373-GG)
significantly associated with suicidal events [26].
CRHR1 codes for a G-protein-coupled receptor in-
volved in the regulation of the HPA axis by mediating
the effects of corticotropin-releasing hormone (CRH)
[27]. Raised levels of CRH in regional brain and cerebro-
spinal fluid (CSF) are a consistently replicated finding in
patients with depression, and is also seen in suicide vic-
tims [28-31], rendering CRHR1 an attractive candidate
gene for MDD susceptibility. In 2006, Liu et al. identi-
fied three SNPs in CRHR1, which were significantly
more common in a group of 206 Han Chinese patients
with MDD compared with 195 controls matched for age,
gender and ethnicity [32]. Subsequently, Papiol et al.,
compared CRHR1 SNP frequencies in 159 Spanish out-
patients with MDD and 96 healthy controls, and found
an association between the CRHR1 SNP rs110402 and
early age of MDD onset. This SNP was also associated
with increased risk for a seasonal pattern of illness [33].
Following these findings, Lekman et al. analyzed clinical
data from 1,809 outpatients with MDD and a collection of
739 ‘Black’ and ‘non-Hispanic White’ ethnically matched
controls enrolled in the STAR*D (Sequenced Treatment
Alternatives to Relieve Depression) study. These authors
found that the SNP rs1360780 was associated with MDD
susceptibility in the non-Hispanic White sample, and the
SNP rs4713916 was associated with disease remission to
citalopram in the overall patient sample [34].
A consistent finding that clearly contributes to the HPA
axis hyperactivity in MDD is hypersecretion of CRH. The
CRH-binding protein (CRHBP) regulates the availability
of CRH, both centrally and in the systemic circulation,
which modulates HPA axis activity. SNPs in CRHPB
were first associated with MDD in a case–control study
conducted in a Swedish population [35]. Claes et al. exam-
ined 89 Swedish patients with recurrent MDD and 88
control samples matched for age, gender and ethnicity,
and found two SNPs that were marginally associated with
MDD. The authors reported one haplotype block com-
prised of the CRHPB SNPs s02-TT, s11-TT, and s14-T,
whose presence significantly increased susceptibility to
MDD [35]. In 2007, Van Den Eede et al. sought to repli-
cate the CRHBP Swedish study findings in an extended
Swedish sample, and in a larger and ethnically distinct
sample (Belgian population). They analyzed 317 patients
with MDD and 696 controls, but were unable to detect
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standing correction for multiple testing) between the
CRHBP SNPs in either the extended Swedish sample or
Belgian sample [36].
Genetics: bipolar disorder
Evidence from family, twin, and adoption studies show
that BD is highly heritable, with genetic variables esti-
mated to account for 60 to 85% of risk [37]. Efforts to
discover the genetic sources for BD risk have led to
innumerable linkage studies, some of which have identi-
fied promising susceptibility loci. However, these link-
age studies have been fraught with inconsistent
replication and indeterminate genetic causes of in-
creased linkage signal [38,39]. Hence, there have been
increasing efforts toward association studies. As with
MDD, genes of the HPA axis have been probed for can-
didates increasing susceptibility to BD. Willour et al. ge-
notyped FKBP5 SNPs in a family sample of 317 BD
pedigrees and 554 affected offspring. They found evidence
for an association with BD for five SNPs (rs4713902,
rs7757037, rs9296158, rs3800373, and rs9380525), with
rs4713902 showing the most robust signal (P= 0.0001).
Furthermore, Willour and colleagues identified four
SNPs (rs1043805, rs3800373, rs9296158, and rs1360780)
in covariate-based analyses that showed differential associ-
ation with BD depending on the covariates of attempted
suicide and/or the number of depressive episodes [40].
However, other studies were unable to replicate the fin-
dings of association of BD with FKBP5 [41,42]. Subse-
quent GWAS in BD have contributed modest evidence of
BD susceptibility attributable to SNPs in FKBP5 [43,44].
Many candidate genes have been derived from the dopa-
minergic, serotonergic, and noradrenergic systems, based
on the evidence for a role of these circuits in BD pathogen-
esis. In particular, the genes encoding 5-HTT, monoamine
oxidase A (MAOA) and catechol-O-methyltransferase
(COMT) have generated both positive and negative asso-
ciation findings with BD. However, there is no conclusive
evidence for indisputable association of any of these genes
with BD susceptibility [39]. Circadian rhythm disturbances
are commonly seen in BD, which has led to multiple stud-
ies of association between circadian rhythm genes and BD
[38,45,46]. The genes coding for aryl hydrocarbon receptor
nuclear translocator-like BmaL1 (ARNTL) and circadian
locomotor output cycles kaput (CLOCK) are two genes
partially responsible for control of the internal circadian
clock in the suprachiasmatic nucleus of the hypothalamus
[47]. Both of these genes have been identified in association
studies of BD. For example, Mansour et al. compared 234
Caucasian individuals with BD with 180 community-based
controls in a BD association study. The authors geno-
typed 44 SNPs from eight circadian rhythm genes:
ARNTL, CLOCK, Period 1, 2, and 3 (PER1, PER2, PER3),cryptochrome 1 and 2 (CRY1 and CRY2) and TIME-
LESS. They found modest associations with SNPs for
ARNTL and TIMELESS, although they cautioned that
additional studies are necessary to corroborate the find-
ings [48]. Shi et al. conducted an association study of 10
circadian genes using the Sibling-Transmission Disequi-
librium Test (sib-tdt) in an extended family collection
(composed of 70 trios and 237 quads) in BD, and identi-
fied nominally significant association of three SNPs near
or within the CLOCK gene; however, these associations
did not survive correction for multiple testing [46].
GWAS in BD have identified four genes for further
study that had SNPs of genome-wide statistical signifi-
cance: calcium channel, voltage-dependent, L type alpha
1C subunit (CACNA1C), ankyrin 3 (ANK3), neurocan
(NCAN) and odd Oz/ten-m homolog 4 (ODZ4) [49-51].
Although not significant at the genome-wide level,
spectrin repeat containing, nuclear envelope 1 (SYNE1),
has been recently associated with BD and with recurrent
MDD [52]. Green et al. tested SYNE1 SNP rs9371601 in
1,527 subjects with BD and compared them with 1,579
non-psychiatrically screened controls, finding evidence
for the association of the SNP with BD (P= 0.0095) [52].
Furthermore, they identified a significant association
between the SNP and recurrent MDD in a sample of
1,159 subjects with recurrent MDD compared with
2,592 controls (P= 0.032). SYNE1 codes for Nesprin-1, a
protein comprising part of the scaffolding that links the
nucleoskeleton to the cytoskeleton (LINC) [53]. The as-
sociation findings in SYNE1 relating to BD and to MDD
are likely to spark subsequent genetic and functional
studies.
Genetics: schizophrenia
With estimates of heritability of 50 to 80%, SZ is one of
the most heritable of the disorders discussed in this
paper [54,55]. Innumerable candidate gene studies and
more than a handful of GWAS have contributed to the
impression that SZ, despite its high heritability, is gene-
tically complex, probably with a large polygenic compo-
nent explaining a substantial amount of susceptibility
[56]. In fact, the International Schizophrenia Consortium
(ISC) tested a polygenic model for SZ by summarizing
nominally significant associations in their GWAS data
into quantitative scores. They then related these derived
scores to disease states in three large, independent target
samples [57]. From these analyses, the ISC concluded that
one-third of genetic susceptibility for SZ lies in the collect-
ive effect of hundreds or thousands of common polygenic
variants, each contributing small effects [56,57]. GWAS
are poised to reveal such variants, and the results of the
SZ GWAS are largely in agreement with the ISC assess-
ment. Three comprehensive analyses of GWAS data from
the ISC, Molecular Genetics of Schizophrenia (MGS) and
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implicated a few discrete genes with odds ratios in the
range of 0.73 to 1.23 [56-59]. These analyses also impli-
cated the genome region (between 26 and 33 million bp)
containing the major histocompatibility complex (MHC),
a group of genes that encodes proteins necessary for the
immune system to recognize foreign substances [56-59].
Clarifying the relationship between the MHC genes and
SZ continues to be an area of active research.
GWAS and linkage studies have homed in on possible
SZ-associated genes and genetic regions outside of the
MHC region that have garnered interest, including the
zinc finger 804A (ZNF804A) gene. The 2008 study of
O’Donovan et al. GWAS identified 12 loci with ‘moder-
ately strong’ (P<10-5) evidence for association in their
primarily European-ancestry sample of 479 SZ and 2,937
controls. Subsequently, one SNP within the intron of the
ZNF804A gene, rs1344706, remained significant in their
larger replication samples (6,666 SZ subjects and 9,897
controls, including 1,782 Chinese and Japanese SZ sub-
jects, and 1,865 controls) at the more stringent ‘strong’
threshold of P<5 × 10-7 (P = 1.61 × 10-7) although not at
genome-wide significance threshold (P<7.2 × 10-8) [60].
The authors then broadened their phenotype to include
BD, and found a strengthening of this association beyond
the genome-wide significance threshold (P = 9.96 × 10-9)
[60]. Several independent replication studies identified at
least nominal associations between ZNF804A and SZ
[61-63]. A 2010 case–control study by Riley et al., com-
pared 1,021 Irish subjects with SZ or poor-outcome
schizoaffective disorder with 626 Irish control subjects,
and reported nominally significant association between SZ
and ZNF804A rs1344706 (P = 0.0227) and two other
ZNF804A SNPs (rs17508595 at P = 0.0230 and rs7597593
at P = 0.0013) [61]. Steinberg and colleagues (2011)
reported an association between rs1344706 and SZ
(P = 0.0029) and SZ plus BD (P = 0.00065) in their sample
(European ancestry with Chinese in follow-up study).
Notably, when stratified by population, only two of the
thirteen ethnicities, that is, Danish and Russian, exhibited
a significant association between rs1344706 and SZ [62].
Zhang et al. conducted a population case–control study
and a family-based study in a Han Chinese population.
They reported a significant over-representation of the
T allele of rs1344706 in their SZ population relative to
controls in the population-based study (P = 0.00083)
and a trend toward positive association in their trios
(P = 0.058) [63]. In the wake of these findings, Williams
et al. performed a meta-analysis of the data from the
discovery GWAS along with data from thousands of add-
itional European-ancestry samples from in-house sources,
five GWAS (ISC, MGS, SGENE-plus, the Lencz et al.
GWAS, one unpublished Swedish GWAS from Sullivan
and Hultman [57-59,64,65]), and a handful of collaborativegroups (totaling 18,309 SZ cases and 35,739 controls). The
meta-analysis supported the original findings for association
between rs1344706 and SZ (P = 2.5 × 10-11; odds ratio
(OR) = 1.10; 95% confidence interval (CI) 1.07 to 1.14) and
with SZ plus BD (P = 4.1 × 10-13; OR = 1.11; 95% CI 1.07
to 1.14) [65]. To date, ZNF804A remains one of the most
promising of the GWAS findings in SZ.
Another gene with genome-wide association with SZ
is transcription factor 4 (TCF4), which is a gene impor-
tant for neurodevelopment [59,66,67]. Mutations in
this gene have been linked to Pitt-Hopkins syndrome, a
neurodevelopmental condition characterized by mental
retardation, epilepsy, hyperventilation episodes, and
distinct facial features [67,68]. With respect to SZ, one
TCF4 intronic SNP (rs9960767; C allele), was found to
be significantly associated in a GWAS and analysis of
nearly 50,000 subjects (data from SGENE-plus, follow-up
samples, ISC and MGS GWAS samples) (P = 4.1 × 10-9;
OR = 1.23; 95% CI 1.15 to 1.32) [59]. Steinberg et al.
(2011) expanded on these findings, evaluating SNPs that
had P-values of less than 1 × 10-4 in the combined sample
(SGENE-plus, MGS, ISC dataset) of Stefansson et al. [69].
In the Steinberg et al. study, an additional 9,246 Caucasian
SZ samples (SZ, schizoaffective disorder, or persistent de-
lusional disorder) and 22,356 controls were assessed,
followed by analysis of another 1,014 SZ and 1,144 control
samples in a subsequent follow-up. These analyses impli-
cated the C allele of the original rs9960767 SNP in SZ, in
the primary, but not in the secondary follow-up (P = 2.5 ×
10-4; OR = 1.16; 95% CI 1.07 to 1.25 and P = 0.5; OR =
1.09; 95% CI 0.85 to 1.41, respectively) [69]. Considered
together, the Stefansson et al. combined sample and the
two follow-up studies yielded a genome-wide significant
association of rs9960767-C with SZ (P = 4.2 × 10-9; OR =
1.20; 95% CI 1.135 to 1.27) [69]. In 2011, Ripke et al. com-
pleted a replication study in Caucasians that also identified
association of TCF4 with SZ (P = 2.29 × 10-5), albeit with
a different SNP, rs12966547 (which is not in linkage
disequilibrium (LD) with rs9960767) [70]. Analysis of their
replication data pooled with their discovery sample (which
has significant overlap with the Stefansson et al. sample),
yielded an association of genome-wide significance
(P = 2.6 × 10-10) [70]. Notably, a TCF4-SZ association
has also been established in a non-Caucasian popula-
tion. Li et al. explored the TCF4 gene in a Han Chinese
population of 2,496 subjects with SZs and 5,184 con-
trols [71]. Interestingly, the TCF4 SNP highlighted by
Stefansson et al. is polymorphic in Caucasians, but is
not polymorphic in the Chinese population [59,71]. In-
stead of using this SNP, Li et al. substituted a nearby SNP,
rs2958182 (which is in complete LD with rs9960767, and
is polymorphic in the Chinese population). This group
found rs2958182 to be significantly associated with SZ in
their Chinese population (P = 3.64 × 10-6), which provides
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gether, these findings continue to fuel genetic and func-
tional exploration of TCF4 in SZ.
Neuregulin 1 (NRG1) is a gene that is also involved in
many neurodevelopmental functions, including regulation
of the expression and activation of glutamate receptors,
neuronal migration, and oligodendrocyte development
[72-76]. Mutant mice heterozygous for NRG1 (or for its
receptor, ERBB4) have fewer NMDA receptors than their
wild-type littermates. Moreover, they exhibit a SZ-like
phenotype, which is reversible with the atypical anti-
psychotic drug, clozapine [77]. Linkage studies in the
1990s and early 2000s originally highlighted the cytogenic
region containing the NRG1 gene, 8p22-21, as a possible
‘schizophrenia susceptibility locus’ (SSL) [78-81]. A more
specific gene-disease association was first suggested in a
2002 Icelandic linkage study in which a NRG1 haplotype,
HapICE (composed of five SNPs and two microsatellite
markers), was found significantly more often in SZ sam-
ples than in control samples [77]. These initial findings
spurred more than 60 additional studies of NRG1 as a pu-
tative schizophrenia risk gene, yielding mixed findings
[82]. By 2011, several large case–control studies [83-88]
(>1000 subjects) had found at least one positive NRG1-SZ
association, whereas comparably sized studies found no
association at all [89-94]. NRG1 analyses in large family-
based studies (>200 families) fared similarly, with nearly
equal positive [95-99] and negative [41,100-102] associ-
ation findings. Meta-analyses by Munafò and colleagues in
2005 and updated in 2008 [103,104], noted a gene-level
association between NRG1 and SZ, but their data did not
support an association between any particular NRG1 SNP
or haplotype with the disease. The results suggest that
analyses at the level of the gene, rather than the level of an
individual SNP, functional variant, or haplotype, might be
a more reliable method of analysis [104].
Over 8,000 polymorphisms spaced over more than
1,000 candidate genes have been systematically analyzed
in SZ (full results of the analyses can be found in the com-
prehensive SZ association study database, SZGene; http://
www.szgene.org) [82]. Notably, Allen et al. highlighted
SNPs in 16 genes with at least nominally significant effects
(OR ranging from 0.7 to 1.52): DRD2, GRIN2B, TPH1,
DTNBP1, MTHFR, DRD1, APOE, DRD4, COMT, TP53,
HP, DAO, SLC6A4, GABRB2, PLXNA2, and IL1B. [82].
One of these genes receiving a great deal of attention is
COMT, in part because of its known functions, and in part
due to its location in the genome. The COMT gene en-
codes a protein responsible for the metabolic degradation
of catecholamines. In addition, COMT is located on
chromosome 22, within a region that when deleted causes
velocardiofacial syndrome. Notably, nearly 25% of the in-
dividuals inheriting the large deletion at 22q11.21 go on to
develop SZ, making the inheritance of this deletion one ofthe greatest risk factors for development of SZ [105]. In
2002, Shifman et al. found a significant association be-
tween a COMT haplotype and SZ in a case–control study
in Ashkenazi Jews [106]. One 5′-UTR SNP involved in
the haplotype (rs737865) has been implicated in a subse-
quent studies, and despite both positive and negative find-
ings, maintains nominal significance by SZGene meta-
analysis, with a modest OR of 1.06 (95% CI 1.01 to 1.11,
P<0.05) [82].
The disrupted-in-schizophrenia (DISC) locus has also
been associated with SZ after its initial characterization
in a large Scottish family with high psychiatric load
[107]. The DISC locus was identified at the breakpoint
of a balanced translocation between chromosomes 1 and
11. The translocation significantly segregated with a
range of psychiatric illness in the family, including SZ,
MDD, and BD [107]. Further analysis showed that the
translocation is in significant LD with SZ, outside of the
effects of the other psychiatric illnesses (log of the odds
ratio score being 3.6) [108]. Fine mapping focused fur-
ther studies on two genes, DISC1 and DISC2, identified
along the chromosome 1 component of the translocation
[109]. DISC1 codes for a protein known to have diverse
roles, including regulation of neuronal axonal and den-
dritic outgrowth, cell proliferation, and cell differenti-
ation [110]. DISC2 is a non-protein-coding gene thought
to be important in the regulation of DISC1 [108,111].
The majority of DISC1 family and association studies
have had positive findings of a relationship between the
gene and SZ [112-130]. However, there have also been a
number of studies which have not been able to show any
significant findings [41,93,131]. To date, there have not
been any positive association studies for DISC2 and SZ
despite one large association study of 1,054 Scottish
individuals (328 with SZ, 726 controls), which did not
find any significant associations between DISC2 SNPs
and SZ [132].
Epigenetic modifications
Although genetics clearly play an important role in per-
sonalized medicine, the role of epigenetics should not be
overlooked. Epigenetics refers to the phenomenon of her-
itable changes to gene regulation caused by mechanisms
that do not involve modification of the nucleotide se-
quence. Increasingly, it is being realized that these mecha-
nisms are far more complex than originally envisioned,
requiring adjustment of the current perspective on the
central dogma of molecular biology; namely, that DNA
transcribes RNA, which is subsequently translated into
protein [133]. It is estimated that approximately 98% of
the human genome is not translated into protein, and
these epigenetic changes occur within the framework of
DNA being transcribed into both coding and non-coding
RNA, with the subsequent translation of coding RNA into
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steps by non-coding RNA [134,135] (Figure 2). Specific
epigenetic mechanisms include DNA methylation, histone
modification, alternative splicing, RNA editing, and non-
transcriptional gene silencing via microRNAs [136]. Epi-
genetic regulation has been implicated in a myriad of
neural processes, from learning and memory to seizures
and neurogenesis, and recently to depression, chronic
stress, and various addictions [137,138].
Epigenetic modifications: major depressive disorder
Study of the epigenetics of MDD, particularly involving
DNA methylation and histone modification, has gene-
rated some interesting findings [6]. Electroconvulsive
therapy (ECT), the induction of controlled seizures to
relieve depressive symptoms, can be remarkably effective
in severe treatment refractory cases of depression [139].
The effectiveness of ECT requires multiple treatments,
and without continued antidepressant therapy or main-
tenance, nearly all patients will have a relapse of their
symptoms [138,139]. Epigenetic changes are thought to
partially account for this phenomenon.
In animal models of depression, chromatin remodeling
of brain-derived neurotrophic factor (BDNF) promoters
leads to site-specific increased BDNF transcription, a
change shown to mediate susceptibility to stress in
humans and in mouse models [6,140]. Another notable
example of epigenetic changes is seen in rats reared by
mothers who exhibit especially high levels of nurturing
behaviors of pup licking and grooming (LG) [141]. The
authors described the adult rat offspring from high-LG
mothers as being less anxious than their low-LG counter-
parts. The high-LG offspring also displayed corresponding
measurable changes to the HPA axis (for example, in-
creased glucocorticoid receptor mRNA and protein ex-
pression, decreased hypothalamic corticotropin-releasing
factor (CRF) mRNA expression and increased sensitivityFigure 2 ‘Modified’ central dogma. The central dogma of molecular bio
into protein. In light of the emerging importance of non-coding RNAs, this
the central dogma, including regulating their own transcription.to glucocorticoid negative feedback), changes that are due,
in part, to gene-expression changes that remain stable
until adulthood. Of note, these gene-expression alterations
are reversible with cross-fostering of rats between high-
LG and low-LG mothers [138,141-143]. Building on these
principal findings, McGowan et al. [144] explored the
epigenetic regulation of a neuron-specific glucocorticoid
receptor gene (nuclear receptor subfamily 3, group C,
member 1; NR3C1) in human suicide victims subjected
to childhood abuse. In their study, they compared post-
mortem hippocampal tissue samples from 12 suicide
victims with a history of childhood abuse, 12 suicide vic-
tims with no history of childhood abuse, and 12 controls
(persons experiencing sudden, accidental death without a
history of childhood abuse). They found that the expres-
sion of total glucocorticoid receptor mRNA was signifi-
cantly lower in the abused suicide victims than in either
the non-abused suicide victims or the controls. Further-
more, the level of methylation of the NR3C1 promoter
sites was significantly higher in the abused suicide victims
compared with the non-abused suicide victims or con-
trols. Notably, in both of these findings, there were no
significant differences between the non-abused suicide
victims and the controls. The authors report that these
findings are consistent with those in animal models show-
ing epigenetic modifications of the glucocorticoid receptor
leading to increased HPA responses to stress. Moreover,
they speculate that early adverse life events, such as child-
hood abuse, may lead to epigenetic changes that contri-
bute to risk for developing psychopathology [144].
Epigenetic modifications: bipolar disorder and
schizophrenia
Because many epigenetic studies of BD also include pa-
tients or tissue samples with SZ, the epigenetic studies in-
volving both disorders are summarized here. The role of
methylation in SZ has been suggested for over 50 years,logy states that DNA is transcribed to RNA, which is then translated
diagram shows how non-coding RNAs serve to regulate each step in
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ing agent, methionine, were noted to experience exacerba-
tion of their psychosis [145,146]. Since that time, many
post-mortem brain studies have focused on methylation
patterns in SZ. For example, differential methylation pat-
terns in the regulatory regions of COMT and reelin (RELN)
have been found between individuals with SZ compared
with controls. From a functional standpoint, dysregulation
of either of these genes could feasibly result in psychopath-
ology. COMT is an important gene for metabolizing cate-
cholamines, while RELN encodes an extracellular matrix
glycoprotein theorized to control cell-cell interactions dur-
ing neuronal positioning and migration during brain devel-
opment [147]. Abdolmaleky and colleagues analyzed 115
post-mortem brain samples from the frontal lobe of indi-
viduals with BD or SZ and controls (35 samples per
group). The membrane-bound (MB)-COMT promoter
was hypomethylated significantly more often in the brains
of individuals with SZ or BD relative to the brains of con-
trols [148]. Generally, methylating DNA sequences tends
to decrease their transcription, and accordingly, this
hypomethylation in the BD and schizophrenic brains
corresponded with higher MB-COMT transcript expres-
sion than seen in the controls [148]. The authors
remarked that the resulting overexpression of MB-COMT
could lead to significant increases in dopamine degrad-
ation. Moreover, the resulting hypodopaminergic state
and frontal-lobe hypoactivity may be amenable to COMT-
inhibitor drugs or preventative strategies to modulate
methylation of the COMT promoter [148]. Lower levels of
RELN mRNA expression and protein concentrations were
found in post-mortem brain samples from patients with
schizophrenia relative to control brain samples, which led
to investigations of whether promoter regions are differen-
tially methylated in such patients relative to controls
[149]. In a small (n = 10) post-mortem study of schizo-
phrenic brains compared with controls, Abdolmaleky et
al. found a significant increase in DNA methylation of
CpG islands in the RELN promoter in brains from individ-
uals with SZ compared with controls [150]. However, nei-
ther set of findings (the hypomethylation of the COMT
regulatory regions and the hypermethylation of the RELN
regulatory regions) have been replicated in subsequent
studies [151,152].
Some studies have suggested that epigenetic dysregu-
lation of the 5-HT2A receptor gene (HTR2A) may
contribute to the pathophysiology in SZ. The focus on
HTR2A is not surprising, as it has been the subject of
many studies, which have provided conflicting evidence
for a small, but significant, association of an HTR2A
SNP, rs6313 (c.102C>T), with SZ in European popula-
tions [82,153-155]. This 102-nucleotide position is near
the promoter region, and is thought to be a putative
methylation site, which is consistent with the lowerlevels of 5HT2A mRNA seen with the C allele (in both pa-
tients and controls). Indeed, in a study on post-mortem
human brain tissue, Polesskaya et al. reported that one
of the key determinants of HTR2A expression was cyto-
sine methylation at rs6313 [156]. Notably, this decrease in
HTR2A mRNA is a property that is exaggerated in SZ
[153,154]. Furthermore, antipsychotic treatment decreases
methylation at the 102C polymorphic site, while HTR2A
mRNA expression increases [157]. Interestingly, this
SNP is in complete LD with a promoter SNP, rs6311
(c.-1438G>A), for which there is also some evidence in
favor of an association with SZ in Caucasian samples
(SZGene 2010 meta-analysis: OR = 1.20; 95% CI 1.07
to1.36]) [82,158]. Carrying the minor allele in rs6311 re-
sults in the creation of a methylation binding site for the
E47 transcription activator at position −1,438, and results
in the loss of a CpG binding site at position −1,439 [158].
These findings indicate how genetic alteration can trigger a
chain of downstream epigenetic effects. Clearly, deciphering
the effects of HTR2A gene-expression dysregulation in SZ
will continue to be a rich source of study.
Histone modification is another epigenetic mechanism
hypothesized to contribute to the pathogenesis of SZ and
BD. Post-mortem studies have shown increased levels of
histone deacetylase, type 1 (HDAC1), an enzyme generally
responsible for silencing gene expression, in the pre-
frontal cortices of patients with SZ [159-161]. Sharma
et al. found a strong negative correlation between HDAC1
and GAD67 mRNA, which encodes an isoform of glu-
tamate decarboxyase (GAD) [160]. Taken together, these
findings provide a possible mechanism for the common
observation of decreased expression of GAD, the rate-
limiting enzyme involved in the synthesis of gamma-
aminobutyric acid (GABA) in the brains of patients with
schizophrenia or BD [162-165]. Furthermore, in an animal
model that used methionine to induce SZ-like behavioral
abnormalities, HDAC inhibitors (HDACi) were sufficient
to attenuate the behavioral abnormalities [166]. Valproate
is a mood stabilizer and a potent HDACi, whose mood-
stabilizing effects in BD and SZ may be based on its
epigenetic properties [167].
MicroRNAs (miRNAs) are important contributors to
epigenetic modifications. Specifically, miRNAs are non-
coding RNA sequences that can broadly regulate gene
expression post-transcription [168]. Studies of miRNA in
BD and SZ have thus far yielded somewhat inconsistent
results [169]. Perkins et al. observed the expression
pattern of miRNAs in the pre-frontal cortex (PFC), and
identified 16 miRNAs differentially regulated in their
sample of 15 patients with SZ or schizoaffective disease,
relative to their 21 control samples. Of the 16 identified
miRNAs, 15 were downregulated in SZ [170]. Studies
conducted by Beveridge and colleagues in 2008 and
2010 showed miRNA dysregulation and altered miRNA
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subgenual superior temporal gyrus) of patients with SZ
[171,172]. Interestingly, many of their identified miRNAs
were upregulated, and those that overlapped with the
Perkins study were upregulated in the Beveridge studies
but downregulated in the Perkins study [170-172]. Fur-
thermore, the identified alterations in miRNA in the
Perkins study suggested a decrease in global miRNA bio-
synthesis whereas the 2010 Beveridge study suggested a
global increase in miRNA biosynthesis in SZ [170,172].
A recent study by Miller et al. explored the expression
of over 800 miRNAs in the dorsolateral PFC (dlPFC) in
RNA samples from 35 patients with SZ, 31 with BD, and
34 controls [173]. The authors identified significant
dysregulation in 10 miRNAs in BD and alteration of the
miRNA-132 in SZ. Notably, there were no significant
miRNA overlaps between BD and SZ. Further analyses,
which ranked the associations of miRNA with BD or SZ
by fold change and uncorrected P-values, identified six
dysregulated miRNAs common to both conditions. In
fact, 754 protein-coding genes are affected by two or more
of these miRNAs, which is significantly higher than would
be expected by chance (P<0.0001), suggesting that co-
dysregulation of these targets may result in pathologic
alterations in functionally overlapping molecular networks
[173]. Reliably associating miRNAs with psychiatric illness
is a relatively new field of study, although there are data to
suggest that other individual miRNAs may be linked with
SZ and or BD (for an excellent review, see Miller and
Wahlestedt [169]).
Clinical diagnostics: endophenotypes/biological markers
Endophenotypes are markers of an illness regardless of
the phenotypic presence or absence of the illness. Because
psychiatric disorders are primarily defined based on symp-
toms, many of which overlap between different disorders,
the concept of defining endophenotypes for the disorders
is an attractive one [174]. Gottesman and Gould in 2003
discussed endophenotypes in psychiatry and outlined cri-
teria for defining endophenotypes. The endophenotype
should segregate with the illness in the population, and
co-segregate with the illness within families; it should
be heritable and more prevalent in affected than in
unaffected families; it should not depend on whether
the illness is currently clinically manifested, and finally, it
should be specific to the illness and capable of being reli-
ably measured [174,175].
Biomarkers are measureable characteristics that reflect
biologic function or dysfunction, response to a thera-
peutic measure, or indication of the natural progression
of disease [176]. Historically, psychiatric illnesses have
been diagnosed on the basis of behavioral signs and
symptoms, rather than on biomarkers, but the over-
whelming evidence that severe psychiatric disorders arein fact brain diseases, has led to considerable efforts to
identify and introduce biomarkers into clinical psych-
iatry [177]. Current biomarkers for psychiatric illness fall
into roughly three categories: metabolite levels, mole-
cular genetics, and imaging findings. There are subtle
distinctions between endophenotypes and biomarker
changes, because endophenotypes are trait markers,
whereas biomarkers may be state or trait markers [175].
However, there exists substantial overlap between these
two categories, and we have therefore combined discus-
sion of each into one section.
Clinical diagnostics: major depressive disorder
Negative mood is a central feature in MDD, and there
have been a number of studies evaluating this as an
endophenotype for depression. Wichers et al. conducted
a study in female twin pairs, assessing the relationship
between daily life negative mood bias and the lifetime
diagnosis of MDD [178]. They studied 259 twin pairs;
17.4% of the sample represented twin pairs of which one
twin had a diagnosis of lifetime depression while the
co-twin did not. The authors found that probands with
co-twins meeting a diagnosis for lifetime depression
exhibited greater negative affect responsiveness to daily
life stressors. This relationship held true after control-
ling for proband continuous depression score, past
depressive score, and exclusion of probands who were
depressed at the time of the study. The authors con-
cluded that increased negative affect reactivity is present
in probands with high familial load for depression, re-
gardless of past or current depression [178]. Further-
more, mood-congruent memory (MCM) bias was first
reported in the 1980s and has been repeatedly demon-
strated in MDD and dysphoria in a multitude of recent
studies [179-183].
Similar to negative mood, anhedonia is a central fea-
ture of the MDD diagnosis and has been proposed as an
endophenotype for MDD. Dryman and Eaton analyzed
data from 49 individuals enrolled in the US National
Institute of Mental Health Catchment Area Program
(NIMH-ECA) during the period 1981 to 1985, and found
that anhedonia often precedes the onset of MDD [184].
Furthermore, some researchers have found an association
between family history for depression and anhedonia in
unaffected relatives [185-187]. McCabe et al. used func-
tional magnetic resonance imaging (fMRI) to compare 13
unmedicated individuals recovered from MDD with 14
healthy controls to evaluate whether deficits in the pro-
cessing of reward-relevant stimuli are present in people
at risk for developing MDD [188]. Compared with the
healthy controls, the recovered MDD individuals showed
decreased neural response in the ventral striatum to plea-
sant stimuli and an increased response in the caudate
nucleus to aversive stimuli. The authors suggested that
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neural basis of reward [188].
CSF concentrations of the norepinephrine metabolite
3-methoxy-4-hydroxphenylglycol (MHPG) has long been
proposed as a biomarker for suicide risk, although stu-
dies have generated conflicting findings [189,190]. In a
2009 study, Galfalvi et al. completed a prospective study
of the relationship between MHPG levels and suicidal
behavior in 184 subjects with MDD or BD experiencing
a depressive episode. They identified that lower levels of
the metabolite were predictive of suicidal behavior in
this population. Additionally, lower MHPG levels corre-
lated with higher medical lethality of the future suicide
attempt. The authors suggested that CSF MHPG may be
useful as a biomarker for risk for short-term suicidal
behavior [190].
Neuroimaging findings are being increasingly pro-
posed as endophenotypes in MDD. Ramel et al. used
fMRI to compare 14 unmedicated remitted-depressed
(RD) individuals with 14 matched, never-depressed (ND)
individuals on a self-referent encoding/evaluation task
completed before and after a sad mood challenge [191].
For a subset of the RD group, after priming with sad
mood induction, bilateral amygdala activation predicted
negative recall bias. Notably, this association was not
present before the sad mood priming, nor was it present
in the ND group for any mood state [191].
Clinical diagnostics: bipolar disorder
BDNF is a protein that contributes to synaptic plasticity
and neuronal survival, and has been implicated in the
pathophysiology of a number of psychiatric illnesses
[192,193]. Because BDNF levels in serum reportedly have
high correlation (r = 0.8) with CSF levels, and are pur-
ported to cross the blood–brain barrier, BDNF is an
attractive candidate for real-time study of BD mood states
[194,195]. Recently, two meta-analyses by Fernandes et al.
[196] and Lin [197] probed whether serum or plasma
BDNF levels could reliably serve as a state marker of
mood episodes in BD. In an analysis that combined stu-
dies of BDNF levels in either serum or plasma, Lin [197]
identified that relative to controls, patients with BD in
either manic or depressive states exhibited significant de-
creases in peripheral blood BDNF levels, and additionally,
that pharmacologic treatment of manic states was acco-
mpanied by a significant increase in BDNF blood levels
(plasma or serum). The Fernandes et al. [196] meta-
analysis comprised 13 case–control studies (548 patients
with BD and 565 controls), and measured serum BDNF
levels during each of the three BD states: mania, euthymia,
and depression. The analysis showed that, relative to
levels in controls, serum BDNF levels were reliably de-
creased during manic and depressive states, and normal
in euthymia. The Fernandes group suggested that serumBDNF concentrations can be used to accurately discrim-
inate between the depressive episodes of MDD and
those of BD (the suggested cut-off of 0.26 resulted in
88% sensitivity and 90% specificity) [198]. This has sig-
nificant clinical implications because the ability to dis-
tinguish between BD and MDD is extremely important,
especially in view of the likelihood of antidepressant
monotherapy precipitating manic episodes in patients
with BD [199].
Various cognitive phenotypes have also been sug-
gested as endophenotypes for BD, including processing
speed, visual learning and memory, verbal fluency, psy-
chomotor retardation, and response inhibition [200]. In
their meta-analysis of BD endophenotype candidates,
Bora et al. [200] noted that of the 18 cognitive tests
reviewed, euthymic patients with BD performed signifi-
cantly more poorly than controls on all but one mea-
sure, the visual copy task. Moreover, the authors found
that response inhibition is the most significant endo-
phenotype for BD, which is significantly impaired in
both patients with BD and unaffected relatives of such
patients, but not in controls. Other proposed endo-
phenotypes with strong support from their meta-
analysis are verbal memory (large effect size in BD
versus controls; modest effect size between relatives
of patients with BD versus controls) and psychomotor
retardation (moderate effect size in BD versus controls, no
significant difference in relatives of patients with BD versus
controls). The investigators recommended longitudinal
studies to determine the relationship between cognitive
impairment and brain connectivity and genetics [200].
Clinical diagnostics: schizophrenia
The possibility that certain cognitive deficits should be
considered as SZ endophenotypes has been supported by
multiple lines of evidence [201,202]. Three meta-analyses
reflect efforts to interpret which cognitive domains are
most consistently deficient in the SZ population relative
to controls [201,203,204]. The meta-analysis by Sitskoorn
and colleagues [203] compiled data from 37 studies, and
identified nine weighted variables (broadly derived from
the three domains of attention, memory, and executive
function) that differed significantly in SZ subjects relative
to controls. The largest effect sizes found were for defi-
ciency in verbal memory recall and executive functioning
in subjects with SZ relative to healthy controls (Cohen’s
d = 0.54, 95% CI 0.43 to 0.66, P<0.0001; d = 0.51, 95% CI
0.06 to 0.50, P<0.0001). Smaller effect sizes for their other
variables ranged from d = 0.28 to d = 0.38 for the remain-
der of the variables (in decreasing effect size): visuomotor
tracking, attention/verbal memory span, verbal fluency,
sustained attention, visual memory, executive function,
and selective attention [203]. Szöke et al. [204] reported in
their meta-analysis six altered cognitive variables in first-
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with the greatest effect sizes seen for semantic and phono-
logical verbal fluency (Hedges’ unbiased g = 0.87, 95% CI
0.64 to 1.10; g = 0.65, 95% CI 0.48 to 0.82, respectively).
The remainder of the effect sizes were smaller, ranging
from g = 0.26 to g = 0.49 for visuomotor speed/executive
function, selective attention, and executive function
(Wisconsin Card Sorting Test categories and perseverative
errors) [204]. The meta-analysis by Fioravanti et al. [205]
identified five cognitive domains in which subjects with
SZ performed significantly worse than controls: memory,
language, attention, executive function, and IQ (with me-
mory having the greatest standardized mean difference
of −1.18 (95% CI −1.31 to−1.05, P<0.00001) [205]. In
2007, Gur et al. [202] assessed neurocognitive function in
349 members of 35 multigenerational families with SZ
and in 154 medically and psychiatrically healthy controls
in an attempt to characterize a neurocognitive profile for
SZ. They found that probands with SZ were the most im-
paired with regard to certain neurocognitive domains, the
control group was the least impaired, and the unaffected
relatives of the probands with SZ were impaired at an
intermediate level between the other two groups. In par-
ticular, the authors reported strong genetic influences on
the variability of performance on memory and emotion
processing accuracy and on speed of attention. Further,
because these measures were associated with SZ, they
could be applied to differentiate between unaffected rel-
atives and controls, and because they appear to be herit-
able, the authors proposed that they could be suitable
for use as endophenotypes for genetic studies [202].
Despite some heterogeneity between studies, others have
identified cognitive deficits in individuals with SZ and their
unaffected relatives compared with controls, consistent
with generalized cognitive impairment in these patients
and their genetically susceptible relatives [206-210].Environmental factors: stress
All of the reviewed psychiatric illnesses are characterized
by various degrees of symptom exacerbation upon
exposure to stress. Often underlying this response is
dysregulation of the HPA axis, an important modulator
of adaptive responses to stress. In fact, increased secre-
tion of cortisol, one of the downstream products of the
HPA axis, has been reported for decades in MDD
[211,212]. Upstream of cortisol in the HPA axis is cortico-
tropin releasing hormone (CRH, also known as cortico-
tropin releasing factor, CRF), which is both an important
regulator of the HPA axis and a key regulator in many
extra-hypothalamic brain areas, including the amygdala,
septum, stria terminalis, and cerebral cortex [213]. In these
areas of the brain, CRH acts as a neurotransmitter, orches-
trating endocrine, immune, and behavioral responses tostress [214]. In fact, injection of CRH into the CNS of ro-
dents produces a host of endocrine and immune changes,
and results in behavioral symptoms resembling those of
MDD in humans [215,216]. In view of this, special atten-
tion has been given to identifying associations in HPA axis
genes, in particular those affecting CRH levels. There have
been numerous studies identifying SNPs in the gene coding
for the CRH receptor 1 (CRHR1), which are associated
with MDD [28]. Some studies have also identified differen-
tial treatment response to antidepressant therapy with vari-
ous CRHR1 haplotypes. Importantly, certain CRHR1 SNPs
and haplotypes appear to modify the adult risk of MDD in
individuals subjected to childhood trauma [217-219]. Brad-
ley et al. [217] conducted a study in a group of primarily
socioeconomically disadvantaged African-Americans with
high rates of lifetime trauma (n = 422), to explore whether
the effects of child abuse on MDD susceptibility is moder-
ated by variation in the CRHR1 gene. Linear regression
analyses identified a significant protective effect of the gene
and environment (G × E) interaction between two SNP
haplotypes each with three SNPs (P<0.001; rs7209436-T,
rs4792887-C, rs110402-A and P<0.005; rs7209436-T,
rs242924-C and rs110402-A), and with the three individual
SNP components of the latter haplotype. In an inde-
pendent sample of primarily Caucasian individuals
[217] (n = 299), the authors found similar findings,
namely significant over-representation of the protective
SNP alleles and haplotypes. Polancyzk et al. [218] repli-
cated the Bradley findings in a sample of English women,
but could not replicate the sample when using a different
measure of child abuse than the Childhood Trauma Ques-
tionnaire (CTQ) used in the Bradley study. The CRHR1
gene interaction with trauma in childhood and with MDD
in adulthood has been scrutinized by two other groups,
who used a dexamethasone/corticotropin-releasing hor-
mone test (DEX/CRH) as a measure of HPA axis activity
[219,220]. Tyrka et al. [219] found that two of the CRHR1
SNPs identified in the Bradley et al. study [217], rs110402
and rs242924, showed a significant interaction with child-
hood abuse and prediction of cortisol response to the
DEX/CRH challenge. Similarly, Heim et al. [220] used the
DEX/CRH measure, and found the same relationship,
although only in men, and suggested that the nature of the
type of abuse experienced is crucial because in their
sample, men experienced more physical abuse than did
women.
In addition to its contribution to susceptibility for MDD
and to epigenetic alterations in MDD (see ‘Genetic and
epigenetics of MDD’) the serotonin transporter gene
5-HTT polymorphism, 5-HTTLPR, has been implicated
in G × E interactions. Specifically, Caspi et al. [221] evalu-
ated the relationship between MDD, the 5-HTTLPR geno-
type, and stressful life events over five years in a group of
847 Caucasian non-Maori individuals involved in the
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prospective longitudinal study. The authors used a moder-
ated regression framework with sex as a covariate, and
reported that the effect of stressful life events was signifi-
cantly stronger in individuals carrying the short allele than
in those carrying the long allele (P = 0.02). Moreover, they
identified that childhood maltreatment predicted adult de-
pression in individuals carrying the short allele but not in
individuals homozygous for the long allele (P = 0.05) [221].
Environmental factors: in utero exposure
Much of the work focusing on in utero exposure to psy-
chiatric illness has centered on SZ, with limited study
of BD. Monozygotic twins are concordant for SZ in ap-
proximately 45% of cases, which indicates a potentially
large contribution from environmental factors in the de-
velopment of the illness [222]. Some studies have sought
data from in utero and perinatal environmental expo-
sures for potential explanations as to how monozygotic
twins can be discordant for SZ. In 1967, the NIMH
completed its first study on monozygotic twins discord-
ant for SZ, examining 14 pairs of monozygotic twins,
and summarizing published reports from 100 pairs of
monozygotic twins discordant for SZ [223]. Comparing
available information on the twin pairs illustrated that
the SZ-affected twin was more likely to have sustained birth
complications (index twin: control twin (I:C) = 4.0, n = 30),
including perinatal asphyxia (I:C = 4.0; n = 15), and to
be more than twice as likely to be the lighter-weight
twin (I:C = 2.1; n = 61; P<0.01) [223]. These data laid the
groundwork for many additional examinations of prenatal
and perinatal insults. Cannon et al. [224] conducted a
meta-analysis of eight prospective population-based
studies of obstetric complications and SZ, and identified
three groups of complications that significantly increased
the risk for SZ: 1) pregnancy complications, including
bleeding, Rhesus factor incompatibility, diabetes, and pre-
eclampsia, 2) abnormal fetal growth and development, in-
cluding low birth weight, congenital malformations, and
reduced head circumference, and 3) delivery complica-
tions, including uterine atony, asphyxia, and emergency
Cesarean section. Although many of the independent
characteristics had modest effect sizes, with OR≥2 (bleed-
ing, Rhesus factor incompatibility, pre-eclampsia, reduced
head circumference, and asphyxia), other characteristics
showed sizeable ORs: diabetes in pregnancy (OR = 7.76,
95% CI 1.37 to 43.90, P<0.03), low birth weight (< 2000g;
OR = 3.89, 95% CI 1.40 to 10.84, P = 0.009), emergency
Cesarean section (OR = 3.24, 95% CI 1.40 to 7.50, P =
0.006), congenital malformations (OR = 2.35, 95% CI 1.21
to 4.57, P<0.02), and uterine atony (OR = 2.29, 95% CI
1.51 to 3.50, P<0.001) [224]. By contrast, another study
found no robust evidence for an association between BD
and obstetric complications [225].Other in utero exposures theorized to be involved in
SZ are maternal influenza and maternal stress. Following
an influenza pandemic in 1957, studies in Finland [226],
England and Wales [227], and the USA [228] suggested
a possible association between SZ development and
prenatal exposure to the influenza virus. However, sub-
sequent studies produced conflicting findings. A 2010
meta-analysis of 13 studies of SZ and maternal influenza
exposure following the 1957 pandemic could not identify
an association risk for SZ and prenatal influenza expos-
ure [229]. The relationship between prenatal exposure
to maternal stress and SZ was also analyzed by meta-
analysis after individual studies produced equivocal fin-
dings. The meta-analysis by Selten et al. [230] could not
identify a statistically significant association, despite
querying various forms of maternal stress (wars, spousal
demise, natural disasters, and undesired pregnancies).
Prediction of treatment response or non-response
(therapeutic and side-effect profile)
Role of genetic alteration in drug-metabolizing enzymes
Many of the SNPs reviewed above and many others have
been associated with predicting treatment response (both
in terms of therapeutic efficacy and side-effect profile) to a
pharmacologic intervention. Beyond the effects specific
to particular illnesses or drugs are the genetic changes
in drug-metabolizing genes that underlie differential re-
sponse to pharmacologic agents. These genetic changes
will be reviewed first, followed by specific polymorphisms
in non-drug-metabolizing enzymes (non-DME) and their
relationship to specific psychiatric illnesses.
The most studied group of drug-metabolizing enzymes
(DME) in psychiatry are the cytochrome P450 (CYP) en-
zyme family [231]. CYP enzymes are expressed predomin-
antly in the liver, although they are also found in many
extra-hepatic locations, including in the brain, where their
levels are approximately 0.5 to 2% of those in the liver
[231]. Moreover, the genes coding for the CYP enzyme
family are highly polymorphic, and the effects of many of
the genetic differences contribute to differential metabol-
ism of psychotropic agents [1,231]. DME phenotypes are
broadly grouped into four categories based on genotype
effect on enzyme activity: 1) poor metabolizers (PM), 2)
intermediate metabolizers (IM), 3) extensive metabolizers
(EM), and 4) ultra-rapid metabolizers (UM) [232].
CYP2D6 is an important member of the CYP enzyme
family, because it is responsible for metabolizing nearly
50% of the most commonly prescribed psychotropics, and
evidence in animal models indicates its involvement in the
biosynthesis of dopamine and 5-HT [232-234]. It is also
highly polymorphic, with 7% of Caucasians falling into the
CYP2D6-PM group [231]. Common substrates metabo-
lized by CYPD26 are tricyclic antidepressants, many
SSRIs, venlafaxine, and antipsychotics. Therefore, when
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ally at risk for side effects secondary to the increased bio-
availability and prolonged elimination half-lives of these
drugs. Theoretically, these patients are also subject to an
exaggerated drug response by the same mechanisms. At
the other phenotypic extreme, the CYP2D6-UM would be
expected to exhibit a poorer therapeutic response to
CYP2D6 substrates [235]. Depending on the enzyme af-
fected, this simplified scheme can be used as a basis for
preliminary predictions of the effect a particular genotype
will have on responsiveness to pharmacologic treatments.
However, despite theoretic considerations of using genetic
alteration in CYP enzymes, there has thus far been insuffi-
cient evidence for clinical applicability of CYP genotyping
prior to prescribing either antidepressants (in particular,
SSRIs) or antipsychotics for their respective applications
[236-238].
Role of genetic alteration in treatment response in major
depressive disorder
The response to antidepressants in MDD has been
reported to vary as a function of specific genetic alter-
ations in certain candidate genes (comprehensively
reviewed by Porcelli et al. [239]). Genes that have an
effect on serotonin signaling have been a major focus
of study for the pharmacogenomics of depression. The
polymorphism in the 5′-promoter region of 5-HTT,
5-HTTLPR, has been shown reliably to influence not only
susceptibility for developing MDD, but also response to
antidepressant therapy. A number of studies have linked
the 5-HTTLPR long (L) allele with greater therapeutic re-
sponse to SSRIs [234,240-252]. Other studies have indicated
that the 5-HTTLPR short (S) allele is associated with poorer
or slower therapeutic response to SSRIs [250,251,253-258].
However, a number of discordant studies have appeared. In
a population of Korean patients, Kim et al. [259] found that
the 5-HTTLPR S-allele conferred a greater therapeutic
response to SSRIs. Yoshida et al. [260] found this same
association in a population of Japanese patients and
Lotrich et al. [261] also found this association in older
patients. Moreover, a number of studies failed to show any
relationship between 5-HTTLPR genotypes and antidepres-
sant response or side effects [262,263]. Such discrepant
findings may be related to particular ethnic or age-specific
populations, and these factors should also be considered
when evaluating genetic response to antidepressants.
There is also evidence for a pharmacogenomic role for
genetic polymorphisms in the serotonin receptors HTR1A
and HTR2A, although there are inconsistencies in these
findings as well. Some studies showed an association be-
tween the HTR1A rs6295-C/C genotype and increased
therapeutic response to SSRIs in Chinese populations
[246,264,265] but Kato et al. [266] found the alternate
genotype, rs6295-G/G, to be associated with increasedresponse to SSRIs. However, other groups have been un-
successful in identifying a relationship between SSRIs and
polymorphisms in HTR1A [267-269]. The data for HTR2A
presents similarly, with many authors observing that par-
ticular genetic alterations, including the rs6311-G allele,
the rs9316233-G allele, rs2224721, rs1923884, rs7997012,
rs6313, rs799701, rs3125, rs1923882, and rs6314, are
associated with increased response to SSRIs [269-273].
Murphy et al. [274] compared the SSRI paroxetine with
the tetracyclic antidepressant mirtazapine in an 8-week
double-blind randomized control trial, to identify poten-
tial genetic predictors of efficacy and side effects. This
group characterized variation in HTR2A in 246 older
patients with MDD undergoing the trial, and found that
discontinuing use of paroxetine was significantly associ-
ated with the HTR2A rs6313-C allele in a dose-dependent
manner. Moreover, carriers of the HTR2A rs6313-C/C
genotype experienced more severe side effects than did
those with the other genotypes. Notably, there was no
significant influence of the HTR2A rs6313 genotypes on
mirtazapine side effects [274]. Such findings stand in con-
trast with other groups, who did not observe an effect of
HTR2A variation on antidepressant response [246,275-277].
Because HPA axis disruption has been associated with
MDD susceptibility and pathogenesis, genetic targets
within the HPA axis represent plausible candidates for
differential antidepressant response. Notably, polymor-
phisms in the FKBP5 gene have been associated both
with increasing susceptibility to MDD (whose conferred
susceptibility is further attenuated by environmental
stress) and with differential response to antidepressant
therapy [24,278-280]. In fact, Binder et al. [24] charac-
terized a significantly faster response to SSRIs, TCAs,
and mirtazapine in patients with MDD who were homo-
zygous (TT) for the FKBP5 marker rs1360780 compared
with the heterozygotes (TC) and homozygote major
allele carriers (CC) combined. In a pharmacogenetic asso-
ciation study of genetic variants in CRHBP and response
to citalopram, Binder and colleagues [281] identified a SNP
significantly associated with both remission and reduction
of depressive symptoms in Hispanic and African-American
outpatients with MDD.
Finally, the endogenous opioid system has been impli-
cated in MDD, making the μ-opioid receptor, OPRM1, an
attractive target for evaluation of antidepressant response
variance secondary to genetic variance [282]. Garricock et
al. [282] genotyped 53 separate SNPs in the OPRM1 gene
in 1,631 STAR*D samples, and found significant associa-
tions for polymorphic variation in OPRM1 and citalopram
response and remission. Moreover, the association between
the commonly studied SNP rs1799971 and citalopram
treatment outcome provided some evidence that this effect
is influenced by ancestry groups. The authors expressed
some caution in the interpretation of the findings, because
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OPRM1 variants met genome-wide significance, and the
associations identified could reflect a placebo effect [282].
Of note, there are four published GWAS for SSRI
antidepressant response, three of which stem from as-
sessment of the samples involved in the STAR*D study
and one from the Genome-Based Therapeutic Drugs for
Depression (GENDEP). Despite the number of GWAS,
only one marker in the Papilin (PAPLN) gene had a suf-
ficiently robust association with antidepressant response
(to suicidal ideation) to survive correction for multiple
testing [270,283-285]. This highlights a benefit of the
GWAS approach to pharmacogenomic inquiries; based
on a candidate gene approach, PAPLN, which encodes a
proteoglycan-sulfated glycoprotein, would probably have
been overlooked. However, the paucity of significant fin-
dings also emphasizes the likely multifactorial nature of
antidepressant response, not easily uncovered with current
GWAS designs [286].
Role of genetic alteration in treatment response in
bipolar disorder
Similar to antidepressant response in MDD, numerous
candidate genes have been evaluated for the effect of their
genetic variation on BD therapy, most of which have
focused on lithium [1]. Lithium response to variation in
candidate genes has some notable associations including 5-
HTTLPR, CLOCK, BDNF, X-box binding protein 1 (XBP1),
glycogen-synthase kinase 3 beta (GSK3B), breakpoint clus-
ter region (BCR), cAMP responsive element binding pro-
teins 1to 3 (CREB 1, 2, and 3) and neurotrophic tyrosine
kinase receptor, type 2 (NTRK2) [287-294].
Role of genetic alteration in treatment response in
schizophrenia
Numerous studies have begun to pinpoint associations be-
tween genetic variants in some individuals with SZ and
the tolerability and therapeutic efficacy of antipsychotic
medications [295-298]. Tardive dyskinesia (TD) is an often
debilitating motor disorder characterized by hyperkinetic,
repetitive, and involuntary movements, which is expe-
rienced by approximately 30% of individuals with chronic
SZ on long-term antipsychotic treatment (usually with
first-generation antipsychotics) [299]. There are several
studies providing evidence for genetic variation affecting
susceptibility to TD in response to antipsychotic treat-
ment. For example, polymorphisms near the DA receptor
D2 gene (Taq1A, minor allele, rs1800497) and in the DA
receptor D3 gene (DRD3-Ser9Gly, rs6280) have been
linked with protection against TD and increased suscepti-
bility for developing TD, respectively [300-302]. However,
Woo and colleagues [303] were unable to find any associ-
ation between the DRD3 Ser9Gly in their study of 113
Korean patients with SZ. Moreover, data analysis from theNIMH Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE), a double-blind study that com-
pared the first-generation antipsychotic perphenazine with
four second-generation antipsychotics, did not find evi-
dence for association with TD for either polymorphism
[304,305]. Other genetic variations positively associated
with TD have been identified in the genes for the COMT
catecholamine-degrading enzyme (Met158Val, Val allele),
the manganese isoform of superoxide dismutase (MnSOD),
a mitochondrial enzyme involved in oxidative metabolism
(homozygote Ala genotype at rs4880, MnSOD-Ala9Val,
with a protective effect for Val carriers) and the seroto-
nergic receptor gene 5-HT2A (C allele at promoter region
T102C, rs6313 in older patients) [306-310]. However,
conflicting reports have also been published for the
MnSOD and 5-HT2A variants [311,312].
First-generation antipsychotics are associated with a risk
for TD, whereas several of the second-generation antipsy-
chotics (and first-generation antipsychotic, chlorpromaz-
ine) can increase the risk for the metabolic syndrome and
or isolated weight gain in nearly one-third of patients with
SZ [313-315]. Studies of association of genetic variation
with these side effects include associations with polymor-
phisms in the gene for the serotonin receptor subtype 2C
(HTR2C) and in the gene for leptin (LEP), which is im-
portant for satiety and adipose regulation. These asso-
ciation studies have reported positive associations with
metabolic syndrome (HTR2C intragenic polymorphism
rs1414334-C for risperidone and clozapine), less weight
gain with HT2RC SNPs (HTR2C −759 C→T and −697
G→C promoter polymorphisms, rs3813929-Tand rs518147-
C [316-318], respectively), and increased weight gain with
the LEP promoter SNP −2548 A→G (G allele) ([317,319]).
However, contradictory findings have also been published
[320,321]. Furthermore, Opgen-Rhein et al. [322] were
unable to replicate the LEP association with increased
weight gain.
Agranulocytosis, or severe reduction in a particular class
of white blood cells, is a serious side effect occurring in
approximately 1% of individuals receiving treatment with
the atypical antipsychotic clozapine. This property limits
clozapine’s clinical use despite its clear therapeutic efficacy
in refractory patients [323,324]. Evidence for genetic
variants conferring resistance or increasing susceptibility
to clozapine-induced agranulocytosis (CIA) is reflected in
a number of studies, although the relatively low incidence
of CIA has limited study sizes and effective replication
studies. The human leukocyte antigen (HLA) system is
comprised of a host of genes that are important in im-
mune system modulation, and it has thus far produced
the most promising genetic associations with CIA [325].
These associations include several genetic variants involv-
ing the HLA-DQB1 locus, and have become incorporated
into a commercially available test, although the clinical
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its low sensitivity [325,326]. Additionally, a small GWAS
provides preliminary confirmation of the HLA-CIA asso-
ciation [327].
In a double-blind study, the NIMH CATIE compared
the first-generation antipsychotic perphenazine with four
second-generation antipsychotics: olanzapine, risperidone,
quetiapine, and ziprasidone [304]. The CATIE trial is a rich
resource explored by researchers interested in determining
why there were differential responses to antipsychotics. A
2009 analysis of data from the CATIE study was unable to
find any significant association (following correction for
multiple testing) between 2,769 potential SNPs and 21
pharmacogenetic phenotypes [328]. A GWAS, also dra-
wing from CATIE data, analyzed 738 subjects with SZ for
association between SNPs and antipsychotic response, and
identified one significant locus at rs17390445 associated
with improved SZ-positive symptoms to ziprasidone treat-
ment, although the specific biological relevance of the
locus is unclear [329].
Studies of the gene encoding a voltage-gated potassium
channel, subtype H (KCNH2), have generated some dis-
cussion about the possibility of detecting likely responders
to atypical antipsychotic therapy. Previous reports of SZ-
KCNH2 SNP associations, along with knowledge that anti-
psychotics bind to KCNH2-encoded channels, fueled
inquiry of how risk alleles in KCNH2 might predict treat-
ment response in SZ [330,331]. Apud et al. [332] analyzed
data on the relationship between various KCNH2 geno-
types and atypical antipsychotic treatment response from
two sources: the 364 patients of the CATIE study and an
NIMH cohort of 54 partially treatment-resistant patients
with SZ enrolled in a double-blind, placebo-controlled,
crossover study (antipsychotics included olanzapine,
quetiapine, risperidone, ziprasidone, and aripiprazole).
The authors found that individuals with a TT genotype for
rs1036145 (T allele previously established as an SZ-risk
allele) exhibited significantly greater symptom improve-
ment than those with either the TC or CC-genotypes
(P = 0.0395) [332]. Specifically, two groups of patients
homozygous for rs1036145-TT from the NIMH cohort
(those receiving placebo first and those receiving active
drug first), showed greater change in positive symptom
ratings on the Positive and Negative Syndrome Scale
(PANSS) compared with their heterozygote and CC-
genotype counterparts. Similarly, in the larger CATIE
group, patients with the rs1036145-TT or rs3800779-TT
genotypes also showed greater improvement in positive
symptoms and general psychopathology than their coun-
terparts (rs1036145-TC/CC or rs3800779-TC/CC, respec-
tively). Furthermore, patients carrying the rs1036145-TT
homozygous genotype were far more likely to remain on
their medication than the homozygous non-risk genotype
(rs1036145-CC) (hazard ratio = 0.208,P = 0.033) [332].The similar relationships of atypical antipsychotic treat-
ment response with KCNH2 genotypes in two separate
trials is encouraging evidence that genotyping may help
guide therapeutic decisions in SZ.
Finally, meta-analyses on the DA D2 and D3 receptor
polymorphisms have been conducted, seeking association
with therapeutic response to antipsychotics [333,334].
Zhang et al. [333]carried out a meta-analysis of 10 studies
to determine the relationship between the DRD2 polymor-
phisms, Taq1A and –141C Ins/Del, and antipsychotic re-
sponse. They were unable to detect any relationship
between clinical response and the Taq1A polymorphism
A1/A1 genotype and A1 carriers compared with A2/A2
genotype (pooled OR = 1.39, 95% CI 0.91 to 2.13, P = 0.13
and pooled OR = 1.30, 95% CI 0.92 to 1.84, P = 0.14, re-
spectively), despite previous association findings of clinical
response to haloperidol in acute psychosis, risperidone
in first-episode antipsychotic-naïve patients with SZ, and
aripiprazole in patients with acutely exacerbated SZ
[333,335-337]. They did report a significant relationship
between the -141C Del carriers compared with patients
with the 141C Ins/Ins genotype: -141C Del carriers tended
to have poorer therapeutic response to antipsychotics
compared with 141C Ins/Ins carriers (pooled OR = 0.65,
95% CI 0.43 to 0.97, P = 0.03) [333]. Results for associ-
ation of the DRD3 polymorphism, Ser9Gly, with anti-
psychotic treatment response have been equivocal. An
initial meta-analyses conducted by Jönsson et al. [338]
found that people with the DRD3 Ser9 allele, the Ser/Ser
and Ser/Gly genotypes were more likely to respond to
typical antipsychotics, and less likely to respond to cloza-
pine compared with their counterparts. However, a more
recent meta-analysis by Hwang et al. [334] was unable to
identify any significant association between the Ser9Gly
polymorphism and antipsychotic drug response after
increasing the sample size from 233 to 758 by including
original analyses and studies published after the Jönsson
meta-analysis.
Emerging applications
The types of applications that will greatly affect the pro-
spect of personalized medicine in psychiatry will involve
continued improvements in genomic inquiries and contin-
ued development of genomic testing protocols. Apart from
increasing efficiency in genomic techniques, expanding the
substrate types for study to include transcriptomics and
proteomics (the study of all expressed messenger RNA
(mRNA) and all proteins, respectively), will exponentially
improve the knowledge base and ability to make informed
decisions in personalizing psychiatry [339]. Furthermore,
studies that take a multidisciplinary approach, combining
the categories (for example, gene × environment interac-
tions or endophenotypes × environmental interactions.)
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provide new perspectives and will increase the database
from which to draw further studies. Moreover, develop-
ment of tools to manage and integrate this information
and the development of pharmacogenomic tests for use in
clinical practice will be greatly beneficial in generating
clinically relevant decision trees for use in personalized
psychiatry [340]. For example, targeting the molecules
responsible for epigenetic regulation may prove to be a
promising means of modifying outcomes in psychiatric
illnesses [134]. In addition, studies that relate genetics not
only to pharmacologic therapy, but to other psychothera-
peutics, including various psychotherapies (such as cogni-
tive behavioral therapy and dialectical behavioral therapy),
light therapy, deep-brain stimulation, electroconvulsive
therapy, and transcranial magnetic stimulation (TMS), will
serve to further refine and optimize psychiatric care. Fi-
nally, the importance of developing neuroimaging methods
and their application to psychiatry will continue to have
significant effects on personalizing psychiatry, and this is
discussed in greater detail below.
Imaging genetics in psychiatry
A rapidly advancing area likely to have a major influence
on personalized medicine in psychiatry is neuroimaging,
and more specifically, neuroimaging genomics. Briefly,
imaging genetics uses imaging measures as quantitative
biological phenotypes. It seeks to incorporate genetics,
psychiatry, and neuroscience in a way that relates gen-
etic variation with protein function, brain structure and
connectivity, and psychopathology [341]. Neuroimaging
genetics allows conduction of experiments that relate
genetic change to outcomes of measurable, repeatable
tests of brain structure or function. Two major neuroim-
aging genetic approaches are 1) identification of imaging
alterations in a population with a well-defined genetic-
ally determined illness; and/or 2) verification of the
effects of specific genetic changes. A particularly useful
aspect of defining biological phenotypes using imaging is
the distancing of disease from subjective self-report and
inconsistent diagnostics [341]. Furthermore, the ability to
study in vivo change and change over time in psychiatric
illness is paramount given the neuronal plasticity (or lack
thereof) already identified in various psychopathologies.
In essence, neuroimaging genetics has the potential to
lead to better comprehension of the pathophysiology of
common psychiatric disorders by evaluating the relation-
ship between imaging phenotypes and genetic variation.
Once interventions such as antidepressant therapy or
TMS treatment (discussed below) are introduced into the
equation, conclusions drawn from correlations may give
rise to an understanding of causation. Explorations of
concurrent intervention with real-time imaging, such asthe assessment of self-regulation of frontal cortical activa-
tion (using neurofeedback) in nicotine dependence and
craving, coupled with real-time fMRI, have led to this
technology and its applications expanding in exciting new
directions [342]. For example, trials using this type of
volitional reduction with neurofeedback in the treatment
of MDD are under way, building upon previous works by
the same group ([343]; I. Gotlib, personal communication,
2012). One group is conducting additional trials in PTSD
using concurrent TMS-EEG (technique as described by
Johnson et al. [344]), which employs active therapeutic
intervention with concurrent imaging (A. Etkin, personal
communication, 2012) and is probably informed by the
group member’s previous characterization of anxiety using
fMRI [345].
Furthermore, there already exist a number of examples
of imaging genetics with psychiatric implications [341].
We describe several examples that epitomize the types
of studies and progress being made in imaging genetics
(additional notable findings relevant to genes discussed
throughout the review can be found in Table 1). Promin-
ent examples are seen with in MDD, with the association
between smaller hippocampal volumes and polymor-
phisms within the 5-HTTLPR region, and with the
BDNF Val66Met polymorphism [346]. However, there
are some limitations to this field. Neuroimaging genetics
is a relatively new area, subject to initial missteps, in-
cluding false positives and imprecise interpretations.
There is skepticism that functional neuroimaging studies
(for example, those involving fMRI) actually show the
functional change being queried. The output measure of
fMRI is blood oxygen level dependent (BOLD) change,
which is thought to reflect neuronal activation. Of note,
there is a significant lag between the supposed measured
neuronal activity and fMRI change due to the cardiovas-
cular changes necessary to increase BOLD in response
to neuronal activation. Various imaging methods, each
with their own strengths and weaknesses, have the po-
tential to contribute to clarification of this process, often
in complementary ways. For example, where there is
some temporal disconnection between neuronal activa-
tion and BOLD response, diffusion tensor imaging
(DTI), which is sensitive to directional diffusion of water
along neural pathways, exhibits a more proximate rela-
tionship to neuronal activation [347]. MR spectroscopy
(MRS) can provide chemical profiles capable of differen-
tiating between brain pathologies. Although the use of
positron emission tomography/single-photon emission
computed tomography (PET/SPECT) is more invasive
than the other methods described, it has the advantage
of allowing in vivo monitoring of molecular changes
such as receptor or transporter binding density in re-
sponse to therapy [348-350] (a summary of select imaging
findings is given in Table 1).
Table 1 Selection of imaging findings in psychiatric illness
Psychiatric illness Subgroup/genotype Imaging feature Sample Imaging method Reference
Major depressive disorder • Reduced activity in frontal lobes Various PET, fMRI, EEG, SPECT [351]
• Reduced HPC volumes Meta-analyses MRI [352,353]
• Greater reduction in HPC volume with increased duration of
untreated MDD
38 male outpatients MRI [354]
• Increased baseline activity in pulvinar nuclei bilaterally Meta-analysis PET and SPECT [343]
• Increased amygdala, dorsal ACC, and insular response to negative
stimuli compared with healthy controls
Meta-analysis Task-based fMRI [343]
• Reduced dlPFC and dorsal striatum response to negative stimuli
compared with healthy controls
Meta-analysis Task-based fMRI [343]
5-HTTLPR -S or Lg allele: Increased amygdala reactivity to masked emotional faces;
correlated to lifetime psychiatric hospitalization in MDD
35MDD, 32 controls fMRI [355]
5-HTTLPR -S or Lg allele: Increased bilateral amygdala activation after emotional stimuli
(allele effects are additive)
27 MDD on medication fMRI [356]
5-HT1A - 1019G allele:
5-HTTLPR- L/L: Reduced HPC volumes compared with controls 40 MDD, 40 controls MRI [357]
Late onset (LO) MDD 5-HTTLPR- L/L: Reduced HPC volumes compared with S/L or S/S genotypes 63 LO MDD, 72 EO MDD,
83 controls
MRI [358]
Early onset (EO) MDD 5-HTTLPR -S allele: Reduced HPC volumes compared with left allele carriers
Bipolar disorder • Increased size of lateral ventricles (right ventricle only in [359]) Meta-analyses CT and MRI [359-361]
• Increased number of deep white-matter hyperintensities Meta-analyses CT and MRI [360-363]
• Increased number of subcortical gray-matter hyperintensities Meta-analysis MRI [362]
• Increased activity in limbic structures (left side only in [364]) Meta-analyses fMRI and PET [364,365]
• Reduced activity in frontal structures (vlPFC and dlPFC [364])
Pediatric population: • Reduced amygdala volume Meta-analyses MRI [365,366]
Schizophrenia • Reduced frontal-lobe activity at rest and during task activation Meta-analysis MRI, PET [367,368]
• Increased lateral ventricular size Meta-analyses CT and MRI [369,370]
• Increased D2 dopamine receptor density Meta-analysis PET and SPECT [371]
• Reduced frontal gray matter Meta-analyses MRI [372,373]
SZ: • Reduced bilateral HPC volume relative to controls Meta-analyses MRI [374-376]
nonpsychotic 1st deg family: Meta-analysis MRI [370]
BDNF 66Val/Val carriers: • Reduced activation of the cingulate, lateral PFC and lateral
parietal regions during verbal memory task




+/−A, alcohol abuse positive/negative subjects; ACC, anterior cingulate cortex; Cho, choline; CT, computed tomography; DA, dopamine; dlPFC, dorsolateral pre-frontal cortex; EO, early onset; fMRI, functional magnetic
resonance imaging; 1H-MRS, proton MR spectroscopy; HPC, hippocampal; LO, late onset; MDD, major depressive disorder; MRI, magnetic resonance imaging; NAA, N-acetylaspartate; parahippocampal gyrus; PET,




















Table 2 Psychiatric disease susceptibilities
Gene(s) Variant(s) Population(s) EPI EF BM Key findings Outcome Ref.
Major depressive disorder
5-HTT 5-HTTLPR and EF: stressful life
events
Caucasian + Homozygous or heterozygous carriers of the short
allele had higher frequency of depression and
suicidality when exposed to stressful life events.
SIG [221]
5-HTT STin2.9 Caucasian Increased frequency in MDD relative to controls SIG [7]
5-HTT 5-HTTLPR Caucasian Increased frequency in MDD relative to controls SIG [8]
TPH1 microsatellite at 11p15.3-p14 Caucasian community-based
sibships
Association with MDD susceptibility and microsatellite SIG [11]
TPH1 Various Caucasian Six haplotypes associated with MDD risk SIG [12]
TPH2 rs120074175 (p.R441H) Caucasian (90%), AA (8%),
East Asian (2%)
Higher frequency of SNPs in patients with MDD
compared with controls or patients with BP
SIG [15]
TPH2 rs120074175 (p.R441H) Caucasian (84%), Hispanic (6%),
East Asian (5%), AA (3%),
others (2%)
SNP not identified in non-treatment-resistant and
treatment-resistant patients with MDD, or in treatment-
resistant patients with BP, or in controls
NS [16]
TPH2 rs120074175 (p.R441H),
rs1843809 (c.608 + 5263G>T)
Caucasian Higher frequency of SNPs in MDD relative to controls SIG [13]
TPH2 Various East Asian (Korean) No association of the SNPs rs4570625, rs10748185,




Meta-analysis SNPs associated with MDD susceptibility by fixed-
effects modeling; rs4570625 remained significant using
random-effects calculations
SIG [9]







Five clinical groups were compared: MDD, MDD +
psychosis, MDD + HIV, HIV-positive, and HIV-negative.
Genotype frequencies in the MDD and the MDD +
psychosis groups differed from published allelic
frequencies
SIG [25]
FKBP5 rs1360780 (c.106-2636A>G) Caucasian inpatients with MDD,
BD, or dysthymia
Carriers of the TT genotype experienced more
depressive episodes, by a factor of 2:1 compared with






Genotypes were associated with suicidal events SIG [26]
FKBP5 rs9470080, rs9394309,
rs7748266, rs1360780;
BM: reduced daytime cortisol
secretion
Caucasian older people + Minor alleles were associated with decreased daytime





and EF: prolonged stress
exposure
East Asian (Korean) + Two SNPs were associated with anxiety and depression





















Table 2 Psychiatric disease susceptibilities (Continued)
CRHR1 rs110402 (GG), rs242924 (GG);
and EF: childhood trauma;
and BM: response to DEX/
CRH test
Healthy Caucasians with history
of early life stress
+ + In adults who had experienced maltreatment, the GG
genotypes were associated with increased cortisol
response to DEX/CRH test
SIG [219]
CRHR1 rs10473984 EF: childhood
trauma
+ SNP works synergistically with childhood trauma to
increase risk of MDD
SIG
CRHR1 rs110402 (c.34-4338G>A);
EF: childhood abuse; and
BM: cortisol response to DEX/
CRH test
1: AA, 2: ethnically diverse + + In adult men who had experienced child abuse, the A
allele was associated with reduced MDD symptoms
and reduced cortisol response to DEX/CRH test
SIG [220]
CRHR1 rs110402 (c.34-4338G>A),
rs7209436 (c.33 + 8207C>T) and
rs7209436-rs110402-rs242924
(TAT); EF: childhood abuse
AA, Caucasian + Rare alleles were protective in a dose-dependent
manner against MDD in the presence of child abuse
SIG [217]
CRHR1 rs7209436-rs110402-rs242924
(TAT); EF: childhood abuse
Caucasian (>90%) + TAT haplotype was protective against MDD in women
exposed to severe maltreatment, but not in a
replication study using different measure of trauma
SIG [218]
CRHR1 rs242939 (c.241 + 1631C>T),
three haplotypes
East Asian (Chinese) Allele and genotype association with MDD SIG [32]
CRHR1 rs110402 (c.34-4348G>A) Caucasian Association between SNP and early onset of MDD and
increased risk for a seasonal pattern
SIG [33]
CRHPB Haplotype block Caucasian (Swedish) In patients with recurrent MDD, haplotype block (s02-
TT and s11-TT and s14-T) was significantly associated
with disease compared with controls
SIG [35]
CRHPB Haplotype block Caucasian (Swedish and Belgian) Could not replicate findings of [35] in an extended
Swedish or Belgian sample. Found higher frequency of
haplotype block (s02-TT, s11-TT and s12C) in Swedish
men compared with control men
NS [36]
HTR3A 42 (CC); EF: early life stress
(ELS); BM: frontolimbic
gray-matter alterations
Healthy Caucasian + + Genotype + ELS was a predictor of depressed mood.
Carriers had greater frontolimbic gray-matter
alterations, which were increased by ELS
SIG [379]
SYNE1 rs9371601 (c.1653 +
2159C>A)
Caucasian Higher frequency of SNPs in recurrent MDD relative to
controls
SIG [52]
NR3C1 EPI: NR3C1 promoter site
methylation; and EF: history
of childhood abuse
Suicide victims + + In abused victims, NR3C1 promoter methylation was
increased and glucocorticoid receptor mRNA reduced
compared with non-abused victims or controls
SIG [144]
– BM: CSF concentration of CRF Various + Increased CSF concentration of CRF is a replicable
finding in MDD. Also seen in suicide victims
SIG [28-31]
– EF: birth trauma Monozygotic twins discordant for
MDD
+ Increased occurrence of birth trauma in SZ-affected
twin
SIG [223]
– EF: obstetric complications,

























Table 2 Psychiatric disease susceptibilities (Continued)
– BM: CSF concentration of
norepinephrine metabolite
MHPG
Caucasian (81%) with MDD (85%)
or BD (15%)
+ Lower levels of MHPG were predictive of suicidal
behavior, and correlated with higher medical lethality
of suicide attempt
SIG [190]







Family trios and quads with BD-I,
or BD-II + rMDD, or SZA-BD
SNPs associated with BD in populations studied (BD-I,
BD-II + rMDD, SZA/BD); rs4713902 remained significant
after correction for multiple testing
SIG [40]
FKBP5 various Caucasian (Ashkenazi Jewish) No significant SNP or haplotype associations with BD or
SZ identified
NS [41]
FKBP5 rs4713916 (c.20 + 18122T>C),
rs1360780 (c.106-2636A>G),
rs380037
Caucasian No significant association between SNPs and BD NS [42]
ARNTL rs7107287 (c.-208 +
13499G>T), rs895682 (c.-135
+ 13626T>C), rs1481892 (c.-
208 + 2451G>C), rs4757142
(c.-207-5839G>A)
Caucasian family trios SNPs rs7107287 and rs895682 showed significant
transmission bias in family samples. In Pittsburg sample,
genotype distribution of SNPs rs1481892, rs7107287




rs774026 (c.1578 + 22T>C),
rs2291739 (p.P1018L)
Caucasian family trios SNPs (rs2279665, 2291738) showed transmission bias in
family samples. Haplotype over-transmission involving




rs4340844 (c.559 + 996T>G)
Family trios and quads Suggestive evidence for transmission disequilibrium SUG [46]
SYNE1 rs9371601 (c.1653 + 2159C>A) Caucasian Higher frequency of SNP in BD compared with controls SIG [52]




+ Reduced methylation of COMT promoter in BD
compared with controls led to higher MB-COMT
expression in BD compared with controls
SIG




+ Promoter methylation did not differ between BD and
control brains
NS [151]
– EF: obstetric complications Meta-analysis + No findings to suggest higher risk for BD relative to
MDD or controls after exposure to obstetric
complications
NS [225]
– BM: peripheral blood levels of
BDNF
Meta-analysis + Relative to controls, patients with BD in manic or
depressed states had reduced serum and plasma BDNF
levels
SIG [197]
– BM: serum or plasma levels of
BDNF
Meta-analysis + Relative to controls, patients with BD in manic or






















Table 2 Psychiatric disease susceptibilities (Continued)
Schizophrenia
GWAS various GWAS of MGS sample
(Caucasian, AA)






rs3130375 (7kb from NOTCH4)
and large sets of nominally
associated ‘score alleles’
Caucasian, AA Imputed SNP rs3130375 reached genome-wide






various Meta-analysis of MGS, ISC, and
SGENE data








PGBD1: rs13211507 (c.642 +
2432T>C), NOTCH4: rs3131296
(c.2866-827A>G)
GWAS of SGENE-plus, ISC, and
MGS (Caucasian)
With combined samples, MHC region SNPs showed
genome-wide significance
SIG [59]
COMT rs165688 (p.V158M) Caucasian with velocardiofacial
syndrome (VCFS) ± SZ




rs737865 (c.-92 + 701A>G),
rs165688 (p.V158M)
Caucasian (Ashkenazi Jewish) G allele in the SNPs was associated with SZ. Haplotype
rs737865-rs165599 (G-G) had most significant overall
association with SZ
SIG [106]
COMT rs737865 (c.-92 + 701A>G) Meta-analysis (Caucasian) Nominally significant association between SNP and SZ
in analyses restricted to European samples
SIG [82]
DISC1 t(1:11)(q43,q21) Caucasian (Scottish pedigree) Translocation found to be in significant LD with SZ SIG [107,108]





Caucasian, replication: family trios
(Caucasian and AA)
+ 704-Ser associated with altered hippocampal structure
and formation in healthy subjects. Association between
704-Ser and SZ. Three-SNP haplotype associated with





Caucasian (Scottish) No co-segregation with SZ or BD or significant
association was detected. SNPs were not in LD
NS [132]





+ COMT promoter methylation did not differ between SZ
and control brains
NS [151]




+ Reduced methylation of COMT promoter in SZ
compared with controls, resulting in increased MB-
COMT expression in SZ compared with controls
SIG [148]
ZNF804A rs1344706 (c.256-19902A>C) GWAS: Caucasian (English);
replication: Caucasian and East
Asian (BUL, GRM, US, AUS, JPN,
CHN, and ISR)
Nominally significant association between SNP and SZ
in samples; genome-wide association when case






Caucasian (Irish) Nominally significant association between SNPs and





















Table 2 Psychiatric disease susceptibilities (Continued)
ZNF804A rs12477914 and rs1366840 as
surrogates for rs1344706
(c.256-19902A>C)
Initial study: Caucasian; follow-up:
Caucasian + CHN
Nominally significant association between SNPs and SZ.
When stratified by population, significant in 2 (RUS and
DNK) of 13 (HUN, NOR, RUS, SWE, FIN, DEU, DNK, GBR,
SCO, ISL, NLD, ITA, CHN) ethnic groups
SIG [62]
ZNF804A rs1344706 (c.256-19902A>C) East Asian (Han Chinese) Nominally significant association between SNP and SZ
in a population-based sample. In a family-based trio
study, trend toward significant over-transmission
SIG/SUG [63]
TCF4 rs9960767 (c.146-23634T>G) Caucasian (BEL, DNK, DEU, IRL,
ITA, FIN, SPA, UK, USA)




(as surrogate for rs9960767)
East Asian (Han Chinese) SNP substituted for rs9960767 as rs9960767 is not
polymorphic in CHN, is in LD with rs9960767, and is
significantly associated with SZ in CHN
SIG [71]








Caucasian Haplotype significantly associated with SZ, with a
relative risk of 2.2
SIG [77]
RELN EPI: RELN promoter
methylation
Post-mortem brain samples + Increased methylation of RELN promoter in SZ
compared with controls, leading to reduced RELN
mRNA expression
SIG [150]
RELN EPI: RELN promoter
methylation
Post-mortem brain samples + By contrast to [150], neither SZ nor control samples
found promoter hypermethylation
NS [152]
HTR2A EPI: cytosine methylation at
rs6313 (c.102>T)
Post-mortem brain samples + 102C carriers have reduced 5HT2A gene expression. In
SZ, there is a greater reduction in carriers than in non-
SZ carriers. Antipsychotics that reduce CpG methylation
lead to increased HTR2A expression





Caucasian Higher frequency of SNP in patients with MDD
compared with controls in discovery sample; not
replicated in replication sample. Trend for rs4570625-
rs4565946 G-C haplotype
SUG [18]
KCNH2 rs1036145 (c.76 + 496G>A) NIMH and CATIE cohorts Carriers of rs1036145-TT genotype showed greater
change on the PANSS than carriers of TC and CC
genotypes. rs1036145-TT and rs3800779-TT showed
significant improvement in positive symptoms
compared with TC/CC genotypes
SIG [332]
– EF: prenatal exposure to
influenza (determined by
ecologic data only)
Caucasian (Finnish) + Exposure to influenza during second and third
trimesters increased risk of hospitalization for SZ
SUG [226]
– EF: prenatal exposure to
influenza (determined by
ecologic data only)
Caucasian (English, Welsh) + Number of births with subsequent SZ development
was higher during influenza epidemic relative to





















Table 2 Psychiatric disease susceptibilities (Continued)
– EF: prenatal exposure to
influenza (serologically
documented)
Caucasian, AA, Others (Native
American, MEX, East Asian)
+ Early to mid-gestational exposure to influenza increased
risk for SZ
SIG [228]
– EF: prenatal exposure to
influenza
Meta-analysis + No association between exposure and SZ identified NS [229]
– EF: prenatal exposure to
maternal stress (wars, spousal
demise, disasters, etc.)
Meta-analysis + Data show no effect of prenatal stress on risk for SZ NS [230]
5-HTTLPR, 5-hydroxytryptophan transporter-linked polymorphic region; AA, African-American; AU, Australian; BD, bipolar disorder; BD-I, BD-II bipolar disorder types I and II; BDNF, brain-derived neurotrophic factor;
BEL, Belgian; BGR, Bulgarian; BM: biomarkers; CATIE, Clinical Antipsychotic Trials of Intervention Effectiveness; CHN, Chinese; CRF, corticotropin-releasing factor; CSF, cerebrospinal fluid; DEX/CRH, Dexamethasone/
corticotropin-releasing hormone; DNK, Danish; EF, environmental factors, ELS, early life stress; EPI, epigenetic factors; FIN, Finnish; GRM, German; GWAS, GWAS, Genome-wide association studies; HIV, human
immunodeficiency virus; ISL, Icelandic; IRL, Irish; ISC, International Schizophrenia Consortium; ITA, Italian; ISR, Israeli; JPN, Japanese; KOR, Korean; LD, linkage disequilibrium; MB-COMT, membrane-bound catechol-O-methyltransferase;
MDD, major depressive disorder; MEX, Mexican; MHPG, 3-methoxy-4-hydroxyphenylglycol;NIMH, National Institute of Mental Health; NLD, Dutch (Netherlands); NS, not significant; rMDD, recurrent MDD; RUS, Russian; SCO, Scottish;
SGENE, Schizophrenia Genetics Consortium; SIG, significant; SNP, single-nucleotide polymorphism; SPA, Spanish; SUG, suggestive; SZ, schizophrenia; SZA-BD, schizoaffective disorder, manic or bipolar type; UK, United Kingdom; USA,
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In this review, we have focused on the components and
tools that are proving to be instrumental in personalizing
medicine in psychiatry. We have discussed the types of
information that can be garnered and eventually used in
tailoring psychiatric therapies to the individual. This infor-
mation can be found in the form of particular genetic and
epigenetic changes more characteristic in the psychiatric-
ally ill or in observable biomarkers that are reflective of ill-
ness. Additionally, environmental influences are evaluated;
in particular, how their interaction with genetic variation
can lead to disease attenuation or exacerbation. Further-
more, we have discussed how the definition of the illnesses
can influence the tailoring of individualized therapies. For
example, many psychiatric disorders show phenotypic
heterogeneity at the same time as having symptoms that
overlap with other psychiatric illnesses that may presum-
ably share some fundamental biologic underpinnings.
Indeed, uncovering the biological basis of individual symp-
toms may prove to be as or more helpful in understanding
the pathophysiology of the illness than forcing a constella-
tion of co-occurring symptoms to fit together under one
biologically plausible explanation. What we will probably
experience is a refining of the diagnostic process; in some
cases, recognizing spectrums of disease and in others,
homing in on specific biological features of an illness.
It should be noted that these categories for defining an
individual’s unique psychiatric phenotype are artificially
separated to facilitate a conceptual framework, and there
is substantial overlap between each category (Table 2).
For example, an illustration of how genetic variation in-
teracts with environmental factors is apparent in CRHR1
polymorphism haplotypes, which are not only associated
with MDD but also interact synergistically with child-
hood trauma to increase the risk of MDD [217,281].
Another example is the dexamethasone-binding capacity
of leukocytes; although this is not used in the diagnosis of
PTSD, it can be used as a biomarker or a proxy measure
for glucocorticoid receptor number. In turn, this measure-
ment might help screen persons likely to develop PTSD,
because greater glucocorticoid receptor density is pre-
dictive of risk for PTSD symptoms in military personnel
returning from deployment [378].
We also discussed the use of pharmacogenomics in
psychiatry. The best-studied pharmacogenomics in
psychiatry are the CYP450 liver enzymes, responsible
for the metabolism of many psychotropic drugs. Various
polymorphisms in these enzymes predispose an individ-
ual to enhanced or poorer therapeutic and/or side-effect
response to certain medications. Despite robust findings
of association with the particular CYP450 genotypes
and altered response to psychotropics, there remains
insufficient evidence to support CYP450 genotype
screening [236,381]. Additionally, many of the geneticalterations described in this review also are relevant to
pharmacogenomic paradigms. Examples include the
poor response to SSRIs seen in Caucasian women with
MDD who are carriers of the 5-HTTLPR short allele, or
the faster response to SSRIs seen in patients with MDD
who are homozygous T for the FKBP5 marker rs1360780
[24,253]. Naturally, there is still work to be done in psychi-
atric pharmacogenomics, as causative treatment strategies
for these disorders have yet to be implemented.
The prospect of personalized medicine in psychiatry
more or less reflects ideals still largely unrealized. Cur-
rently, the field is at the information-gathering infancy
stage. The greatest progress can be expected at the inter-
sections of the categories described above, such as gene ×
environment and genes × biomarkers, which will poise
psychiatry to make biological system-based evaluations.
Furthermore, some of the emerging applications, includ-
ing imaging genomics, strengthen our conviction that the
future for personalized medicine is highly promising.
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